Cargando…
Mogamulizumab, an anti-CCR4 monoclonal antibody, is a potent therapeutic option for adult T-cell leukemia-lymphoma
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4043637/ http://dx.doi.org/10.1186/1742-4690-11-S1-O3 |
| _version_ | 1782318952321384448 |
|---|---|
| author | Utsunomiya, Atae |
| author_facet | Utsunomiya, Atae |
| author_sort | Utsunomiya, Atae |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4043637 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2014 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-40436372014-06-17 Mogamulizumab, an anti-CCR4 monoclonal antibody, is a potent therapeutic option for adult T-cell leukemia-lymphoma Utsunomiya, Atae Retrovirology Oral Presentation BioMed Central 2014-01-07 /pmc/articles/PMC4043637/ http://dx.doi.org/10.1186/1742-4690-11-S1-O3 Text en Copyright © 2014 Utsunomiya; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Oral Presentation Utsunomiya, Atae Mogamulizumab, an anti-CCR4 monoclonal antibody, is a potent therapeutic option for adult T-cell leukemia-lymphoma |
| title | Mogamulizumab, an anti-CCR4 monoclonal antibody, is a potent therapeutic option for adult T-cell leukemia-lymphoma |
| title_full | Mogamulizumab, an anti-CCR4 monoclonal antibody, is a potent therapeutic option for adult T-cell leukemia-lymphoma |
| title_fullStr | Mogamulizumab, an anti-CCR4 monoclonal antibody, is a potent therapeutic option for adult T-cell leukemia-lymphoma |
| title_full_unstemmed | Mogamulizumab, an anti-CCR4 monoclonal antibody, is a potent therapeutic option for adult T-cell leukemia-lymphoma |
| title_short | Mogamulizumab, an anti-CCR4 monoclonal antibody, is a potent therapeutic option for adult T-cell leukemia-lymphoma |
| title_sort | mogamulizumab, an anti-ccr4 monoclonal antibody, is a potent therapeutic option for adult t-cell leukemia-lymphoma |
| topic | Oral Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4043637/ http://dx.doi.org/10.1186/1742-4690-11-S1-O3 |
| work_keys_str_mv | AT utsunomiyaatae mogamulizumabananticcr4monoclonalantibodyisapotenttherapeuticoptionforadulttcellleukemialymphoma |